Related Experiment Video
Updated: May 5, 2026
Induction of Ocular Surface Inflammation and Collection of Involved Tissues
Published on: August 4, 2022
Experiences with rituximab for the treatment of autoimmune diseases with ocular involvement
Laura Pelegrin1, Eva Jakob, Annette Schmidt-Bacher
1From the Hospital Clinic de Barcelona, Universidad de Barcelona, Spain; Department of Ophthalmology, Department of Nephrology, Interdisciplinary Uveitis Center, Rheumatology Department for Internal Medicine V, University of Heidelberg, Heidelberg, Germany; and the Department of Ophthalmology, Triemli Spital, Zürich, Switzerland.
Objective:
To report the efficacy of rituximab (RTX) in the treatment of ocular or orbital inflammation accompanying autoimmune diseases refractory to previous standard immunosuppressive therapy.
Methods:
We reviewed medical records of 9 consecutive patients with noninfectious ocular or orbital inflammation treated with RTX.
Results:
Over a mean followup of 42 months, 7 patients were in clinical remission, 1 had partial response to treatment, and 1 did not respond. Best corrected visual acuity improved ≥ 1 line in 4 patients, was stable in another 4 patients, and worsened in 1. Concomitant immunosuppressive therapy was tapered in 6 cases. Systemic corticosteroids were tapered or kept below 7.5 mg a day in 5 patients 1 year after the first RTX cycle.
Conclusion:
RTX therapy, in patients who are refractory to standard immunosuppressive therapy, was effective and showed a beneficial response to treatment including induction of clinical remission of inflammation in most patients.
